Onconetix, Inc. (ONCO)
ONCO Stock Price Chart
Explore Onconetix, Inc. interactive price chart. Choose custom timeframes to analyze ONCO price movements and trends.
ONCO Company Profile
Discover essential business fundamentals and corporate details for Onconetix, Inc. (ONCO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
18 Feb 2022
Employees
12.00
Website
https://onconetix.gcs-web.comCEO
Karina M. Fedasz
Description
Onconetix, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
ONCO Financial Timeline
Browse a chronological timeline of Onconetix, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 1 Jun 2026
Upcoming earnings on 8 Dec 2025
Earnings released on 14 Aug 2025
EPS came in at -$4.05 , while revenue for the quarter reached $106.49K .
Stock split effective on 13 Jun 2025
Shares were split 1 : 85 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 12 Jun 2025
EPS came in at $21.19 , while revenue for the quarter reached $101.63K .
Earnings released on 2 Jun 2025
EPS came in at -$6.40 , while revenue for the quarter reached $711.98K .
Earnings released on 9 Dec 2024
EPS came in at -$2.24 , while revenue for the quarter reached $406.86K .
Stock split effective on 24 Sept 2024
Shares were split 1 : 40 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 29 Aug 2024
EPS came in at -$9.20 , while revenue for the quarter reached $704.85K .
Earnings released on 20 May 2024
EPS came in at -$6.40 surpassing the estimated -$8.40 by +23.81%, while revenue for the quarter reached $700.43K , beating expectations by +1.11K%.
Earnings released on 9 Mar 2024
EPS came in at -$1.00 , while revenue for the quarter reached $58.47K .
Earnings released on 17 Nov 2023
EPS came in at -$0.28 falling short of the estimated -$0.19 by -47.37%.
Earnings released on 20 Oct 2023
EPS came in at -$0.43 falling short of the estimated -$0.19 by -126.32%.
Earnings released on 31 Mar 2023
EPS came in at -$0.18 surpassing the estimated -$8.20 by +97.82%.
Earnings released on 30 Dec 2022
EPS came in at -$0.21 surpassing the estimated -$10.60 by +98.01%.
Earnings released on 29 Sept 2022
EPS came in at -$0.27 .
Earnings released on 29 Jun 2022
EPS came in at -$0.36 .
Earnings released on 30 Mar 2022
EPS came in at -$0.33 .
Earnings released on 30 Dec 2021
EPS came in at -$0.11 .
Earnings released on 29 Sept 2021
EPS came in at -$0.10 .
Earnings released on 30 Mar 2021
EPS came in at -$0.10 .
ONCO Stock Performance
Access detailed ONCO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.